NCT07226596 Non-Abstinence Outcomes in Methamphetamine Use Disorder
| NCT ID | NCT07226596 |
| Status | Recruiting |
| Phase | — |
| Sponsor | William Stoops |
| Condition | Methamphetamine Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-01-14 |
| Primary Completion | 2031-01-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2026-01-14 with a primary completion date of 2031-01-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.
Eligibility Criteria
Inclusion Criteria: * be age 18 years or older; * self-report methamphetamine use in the week prior to screening; * provide a methamphetamine-positive urine sample at screening; * meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD); * be seeking treatment for their methamphetamine use * be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up * Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate. Exclusion Criteria: * current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians * poor venous access precluding blood draws
Contact & Investigator
William W Stoops, PhD
PRINCIPAL INVESTIGATOR
University of Kentucky
Frequently Asked Questions
Who can join the NCT07226596 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Methamphetamine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07226596 currently recruiting?
Yes, NCT07226596 is actively recruiting participants. Contact the research team at william.stoops@uky.edu for enrollment information.
Where is the NCT07226596 trial being conducted?
This trial is being conducted at Lexington, United States.
Who is sponsoring the NCT07226596 clinical trial?
NCT07226596 is sponsored by William Stoops. The principal investigator is William W Stoops, PhD at University of Kentucky. The trial plans to enroll 300 participants.